Product Description: Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020 Oct;61(10):1468-1475.